Xconomy » Transmolecular http://www.xconomy.com Business + Technology in the Exponential Economy Fri, 10 Feb 2012 21:45:27 +0000 http://wordpress.org/?v=3.0.4 en hourly 1 http://wordpress.org/?v=3.0.4 Radie Named TransMolecular CEO http://www.xconomy.com/boston/2009/04/07/radie-named-transmolecular-ceo/ Tue, 07 Apr 2009 17:22:06 +0000 Rebecca Zacks http://www.xconomy.com/?p=19426 Rebecca Zacks

Cambridge, MA-based TransMolecular, a developer of cancer drugs based on a molecule derived from scorpion venom, said today it has named Robert Radie as its president and CEO. Before joining TransMolecular as a business development consultant, Radie held leadership roles at Prestwick Pharmaceuticals, Morphotek, and Vicuron Pharmaceuticals.

Comments | Reprints | Share:   Retweet  Facebook  LinkedIn  Google Plus  E-mail

UNDERWRITERS AND PARTNERS



]]> http://www.xconomy.com/boston/2009/04/07/radie-named-transmolecular-ceo/feed/ Venom-Derived Drug Trial Gets FDA OK http://www.xconomy.com/boston/2008/12/02/venom-derived-drug-trial-gets-fda-ok/ Tue, 02 Dec 2008 16:44:54 +0000 Ryan McBride http://www.xconomy.com/?p=6575 Ryan McBride

Transmolecular, a Cambridge, MA-based biotech firm, reports that the FDA has agreed to consider a filing for approval of its lead anti-cancer drug (TM601) if the molecule meets goals of a late-stage clinical trial, under the agency’s so-called Special Protocol Assessment process. The trial will test the molecule—derived from yellow scorpion venom—as a treatment for patients with lethal brain tumors called glioblastoma multiforme.

Comments | Reprints | Share:   Retweet  Facebook  LinkedIn  Google Plus  E-mail


]]> http://www.xconomy.com/boston/2008/12/02/venom-derived-drug-trial-gets-fda-ok/feed/